In Vitro Confirmation of Artemisinin Resistance in Plasmodium falciparum from Patient Isolates, Southern Rwanda, 2019

Emerg Infect Dis. 2022 Apr;28(4):852-855. doi: 10.3201/eid2804.212269.

Abstract

Artemisinin resistance in Plasmodium falciparum is conferred by mutations in the kelch 13 (K13) gene. In Rwanda, K13 mutations have increased over the past decade, including mutations associated with delayed parasite clearance. We document artemisinin resistance in P. falciparum patient isolates from Rwanda carrying K13 R561H, A675V, and C469F mutations.

Keywords: Kelch-13 gene mutations; Plasmodium falciparum; Rwanda; antimicrobial resistance; artemisinin resistance; malaria; parasites; vector-borne infections.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimalarials* / pharmacology
  • Antimalarials* / therapeutic use
  • Artemisinins* / pharmacology
  • Artemisinins* / therapeutic use
  • Humans
  • Plasmodium falciparum / genetics
  • Protozoan Proteins / genetics
  • Rwanda / epidemiology

Substances

  • Antimalarials
  • Artemisinins
  • Protozoan Proteins